Lantern Pharma Announces AI Module to Advance Precision Cancer Therapies
Lantern Pharma has launched a powerful new AI-driven module within its RADR® platform to predict the effectiveness of combination therapies involving DNA-damaging agents and DNA damage response inhibitors. This innovation supports faster, more targeted development of cancer treatments—especially as the combination therapy market heads toward a projected $50B by 2030. Using this platform, Lantern has also secured FDA clearance for a Phase 1B/2 trial in triple-negative breast cancer, featuring a promising new drug combo. 
Lantern Pharma Announces AI Module to Advance Precision Cancer Therapies